ArticleJournal of family medicine and primary care2022
Seroprevalence of SARS-CoV 2 antibodies & its determinants in children of 5-to-18-year age group in an urban setting, Kerala.
Article in Journal of family medicine and primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SARS-CoV-2 Seroprevalence of Surinamese Children and Determinants of Seropositivity in the CCREOH/MeKiTamara Cohort.Children (Basel, Switzerland) · 2026Article
- Assessing the Burden of COVID-19 among Children Aged 6-14 Years in Karnataka, India: A Cross-sectional Survey.Indian journal of community medicine : official publication of Indian Association of Preventive & Social MedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There were limited data on the true burden of COVID 19 infection in children since the majority of the infections are asymptomatic or paucisymptomatic. This study aimed to measure the prevalence of SARS CoV2 antibodies in children of the 5-to-18 years age group. Methods: A community-based cross-sectional study was conducted in the field practice area attached to a tertiary care hospital in Kerala. Two hundred four children of the 5-to-18 year age group were enrolled in our study. The data regarding sociodemographic details, symptoms suggestive of COVID 19, exposure to confirmed COVID 19 cases and history of COVID 19 positivity were collected from the study participants. 2 ml venous blood was collected from each participant, and the seroprevalence of SARS CoV2 combined antibodies was assessed using WANTAI antibody test kit. Results: The seroprevalence of SARS Cov2 antibodies in children of 5-to-18 years age group was 41.7% (95% CI,34.9% to 48.43%). The seroprevalence was high in the 13-to-15 year age group, almost similar in both gender and socio-economic groups. The seropositivity was significantly associated with history of confirmed COVID 19 positivity, children with a history of symptoms suggestive of COVID 19 and the presence of positive contact in the household ( Conclusion: Approximately 41.7% of children showed seropositivity to COVID 19 infection. More than 50% of the children remain susceptible. Among seropositive, 56.5% were asymptomatic. Thus there is a need to test even asymptomatic children in COVID 19 positive households.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.